<DOC>
	<DOCNO>NCT01788527</DOCNO>
	<brief_summary>The primary objective study determine RT CGM ( Real Time-Continuous Glucose Monitoring ) improve glycemic control woman T1D pregnant planning pregnancy without substantially increase rate hypoglycemia .</brief_summary>
	<brief_title>Continuous Glucose Monitoring Women With Type 1 Diabetes Pregnancy Trial</brief_title>
	<detailed_description>In woman diabetes , hyperglycemia associate increased rate numerous maternal fetal adverse outcome . Mothers increase risk preeclampsia , polyhydramnios , caesarean section . Infants mother diabetes increase rate congenital anomaly , premature delivery , macrosomia , stillbirth NICU admission . Macrosomia associate numerous adverse fetal outcome include shoulder dystocia , birth injury , neonatal hypoglycemia , hyperbilirubinemia , respiratory distress syndrome NICU admission , asphyxia death . Postprandial blood sugar particular associate increased macrosomia rate . Numerous study show pregnancy outcome reduce improved glycemic control . In particular , pre-pregnancy care show assist woman improve glucose control crucial period organogenesis , associate reduced rate adverse pregnancy outcome include major congenital malformation , stillbirth neonatal death . Technological advance aim reduce glycemic excursion improve glucose control patient diabetes include continuous glucose monitoring ( CGM ) system . We hypothesize real-time CGM assist woman type 1 diabetes improve glycemic control pregnancy .</detailed_description>
	<mesh_term>Pregnancy Diabetics</mesh_term>
	<mesh_term>Diabetes , Gestational</mesh_term>
	<criteria>Clinical diagnosis type 1 diabetes use daily insulin therapy least one year Age 1840 year Insulin regimen involve either use insulin pump multiple daily injection insulin ( least 3 shot per day ) . Subjects use premixed fix dos insulin time enrolment eligible . Insulin regimen must stable least 4 week ( i.e . multiple insulin injection insulin pump ) prior randomization . No expectation subject move area clinical center next year , unless move area serve another study center Informed Consent Form sign subject In addition , specific eligibility criterion apply respective group : Prepregnancy Group : Patients plan pregnancy wish optimise glycemic control conception Pregnancy Group : Pregnancy gestation ≤13 week , 6 day time randomization Live singleton fetus Dating ultrasound ( US ) do confirm gestational age , viability rule multiple . Gestational age base last menstrual period ( LMP ) provide ≤5 day discrepancy US date first trim ≤10 day discrepancy US date second trimester . If date LMP outside limit , US date use best estimate gestational age . Type 2 diabetes Gestational diabetes Previous participation study Estimated GFR &lt; 60 ml/min/1.73 The presence significant medical disorder use medication oral glucocorticoid judgment investigator affect wear sensor completion aspect protocol . If investigator uncertain whether patient would eligible ; i.e . medical disorder would constitute exclusion , Steering Committee ask make decision . Inpatient psychiatric treatment past 6 month Subjects use premixed fix dos insulin time enrolment In addition , specific exclusion criterion apply respective group : Prepregnancy Group : HbA1c &lt; 7.0 % &gt; 10.0 % Pregnancy Group : HbA1c &lt; 6.5 % &gt; 10.0 % Known current high order pregnancy ( twin , triplet , etc . ) These woman exclude high rate adverse outcome could lead inequality unequally distribute group . Known potentially major fetal anomaly ( per EUROCAT criterion ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Type 1</keyword>
	<keyword>CGM</keyword>
	<keyword>Continuous Glucose Monitor</keyword>
	<keyword>HGM</keyword>
	<keyword>HbA1c</keyword>
</DOC>